PMN@NIC-MalNPs improved cardiac dysfunction, reduced myocardial infarct size, and prevented apoptosis by activating the STAT3/Bcl-2 pathway in a mouse model of myocardial infarction.
Does PMN@NIC-MalNPs improve cardiac function and reduce infarct size in myocardial infarction model mice?
A novel ROS-responsive nanoplatform delivering malonate and niclosamide successfully reduced oxidative stress, restored mitochondrial function, and decreased myocardial infarct size in a mouse model of myocardial infarction.
Myocardial infarction (MI) is the leading cause of death worldwide. The most effective way to treat myocardial infarction is to rescue ischemic cardiomyocytes. After an ischemic event, the overproduction of reactive oxygen species (ROS) is a key driver of myocardial injury. The produced ROS affects mitochondrial function and induces apoptosis in cardiomyocytes. This was accomplished by constructing platelet-membrane-encapsulated ROS-responsive drug-releasing nanoparticles (PMN@NIC-MalNPs) to deliver malonate and niclosamide (NIC). The results revealed that PMN@NIC-MalNPs degraded and released malonate and niclosamide in a high-level ROS microenvironment, effectively reducing the oxidative stress and apoptosis rate. By enhancing basal mitochondrial oxygen consumption rate (OCR), adenosine triphosphate (ATP) production, and spare respiratory capacity (SRC) in vitro, reduced the oxidative stress levels and restored mitochondrial function. In vivo studies revealed that the PMN@NIC-MalNPs improved cardiac dysfunction, inhibited succinate dehydrogenase (SDH) activity, increased ATP production, and reduced the myocardial infarct size in myocardial infarction model mice. Further, transcriptome analysis and Western blot revealed that PMN@NIC-MalNPs prevented apoptosis by activating the expressions of the signal transducer and activator of transcription 3 (STAT3) and Bcl-2, and inhibiting the expression of Bax. Thus, this study provides a novel therapeutic solution for treating myocardial infarction and predicting the viability of an antioxidant and antiapoptotic therapeutic solution in the treatment of myocardial injury.
Hu et al. (Tue,) conducted a other in Myocardial infarction. PMN@NIC-MalNPs was evaluated on Myocardial infarct size, cardiac dysfunction, and apoptosis. PMN@NIC-MalNPs improved cardiac dysfunction, reduced myocardial infarct size, and prevented apoptosis by activating the STAT3/Bcl-2 pathway in a mouse model of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: